<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953225</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-004-09S</org_study_id>
    <secondary_id>MUSC IRB HR#19344</secondary_id>
    <nct_id>NCT00953225</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer</brief_title>
  <acronym>vit D &amp; PCa</acronym>
  <official_title>Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated
      phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising
      the possibility that vitamin D deficiency over time promotes the progression of subclinical
      prostate cancer to clinical disease. The investigators propose to conduct a clinical study
      aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans
      diagnosed with low-risk, early-stage prostate cancer, who elect to have their disease
      monitored through active surveillance. The successful completion of this proposed clinical
      study will allow us to determine whether correcting vitamin D deficiency in Veterans
      diagnosed with early-stage prostate cancer will prevent progression of their disease and
      improve their prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D promotes the differentiation of prostate cancer (PCa) cells, maintains the
      differentiated phenotype of prostate epithelial cells, and can induce prostate cancer cell
      death, raising the possibility that vitamin D deficiency over time promotes the progression
      of subclinical PCa to clinical disease. These considerations support the use of vitamin D3 as
      a chemopreventive agent.

      We hypothesize that a daily dose of vitamin D3 (4,000 IU) taken for one year by Veterans
      diagnosed with low-risk, early-stage PCa, who are eligible for active surveillance will: a)
      result in a measurable decrease of serum PSA levels in a significant number of enrolled
      subjects, and b) be associated with a stabilization or improvement of their PCa pathology, as
      assessed through histological examination of prostate tissue biopsy specimens (Gleason score
      and percent of positive biopsies) obtained at the end of the study, as part of their standard
      medical care for active surveillance.

      This VA Merit application proposes to conduct a randomized, placebo-controlled clinical study
      aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans
      diagnosed with early-stage prostate cancer, who elect to have their disease monitored through
      active surveillance (before considering definitive therapy). The main objectives of this
      proposed clinical study are as follows:

        1. To determine whether a daily supplement of 4,000 IU of vitamin D3 taken for twelve
           months will result in a measurable and significant decrease of serum PSA levels in
           Veterans diagnosed with low-risk, early stage PCa (Gleason score 6, PSA 10, clinical
           stage T1C or T2a), who elect to have their disease monitored through active surveillance
           for at least one year.

        2. To determine in enrolled Veterans the pathology status of their PCa by analyzing
           prostate tissue biopsy specimens at the end of the study (Gleason score and percentage
           of positive biopsies), and by comparing them with those obtained before enrollment in
           this study, as part of their standard medical care.

      The implementation of these proposed studies will allow us to assess whether vitamin D3
      supplementation can be utilized as a chemopreventive regimen in Veterans diagnosed with
      low-risk, early stage PCa, and provide a useful addition to active surveillance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2010</start_date>
  <completion_date type="Actual">October 30, 2014</completion_date>
  <primary_completion_date type="Actual">December 15, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA Slope (Trajectory) or the Change in PSA Level Over Time</measure>
    <time_frame>1 year (visits # 1-8)</time_frame>
    <description>Change in PSA (ng/mL) from baseline to 1 year visit, which include the baseline through 1 year follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Positive Biopsy Cores (Out of Twelve) Compared to the Corresponding Values Assessed Before Enrollment</measure>
    <time_frame>1 year</time_frame>
    <description>Change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4,000 IU vitamin D3 daily for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3</intervention_name>
    <description>4,000 IU daily for one year</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo daily for one year</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male Veterans (&gt; 18 years of age) recently diagnosed with low-risk PCa (histologically
             documented adenocarcinoma of the prostate)

          -  A serum PSA value of up to 10.0 ng/ml, and a Gleason score of six or less (three or
             less in either architectural pattern)

          -  For the purpose of eligibility, these additional criteria will be verified: *serum
             creatinine 2.0 mg/dL

               -  serum phosphate (measured as phosphorus) &gt; 2.3 and &lt; 4.8 mg/dL

               -  serum calcium &gt; 8.5 and &lt; 10.5 mg/dL

        Exclusion Criteria:

          -  Subjects with any concurrent malignancy, except non-melanoma skin cancer

          -  Subjects with a history of sarcoidosis

          -  Subjects with a history of high-dose (1,000 IU per day) vitamin D supplementation

          -  Subjects with a history of hypercalcemia

          -  Subjects who use lithium as a medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>diagnosis of early-stage prostate cancer</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastiano Gattoni-Celli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ralph H. Johnson VA Medical Center, Charleston, SC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center, Charleston, SC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401-5799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>February 10, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2015</results_first_posted>
  <last_update_submitted>September 8, 2017</last_update_submitted>
  <last_update_submitted_qc>September 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was based in the Urology Clinics at the Medical University of South Carolina (MUSC) and the Charleston VA Medical Center, and the MUSC Radiation Oncology Clinic, all located in Charleston, SC. The recruitment period was from October 2010 through December 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D3</title>
          <description>4,000 IU vitamin D3 daily for one year
vitamin D3: 4,000 IU daily for one year</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo daily for one year
Placebo daily for one year: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D3</title>
          <description>4,000 IU vitamin D3 daily for one year
vitamin D3: 4,000 IU daily for one year</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily for one year
Placebo daily for one year: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PSA Slope (Trajectory) or the Change in PSA Level Over Time</title>
        <description>Change in PSA (ng/mL) from baseline to 1 year visit, which include the baseline through 1 year follow-up.</description>
        <time_frame>1 year (visits # 1-8)</time_frame>
        <population>Linear regression was applied to each subject's data with Log(PSA +1) as the outcome. Based on the fitted model, the change in PSA from visit #1 (baseline) to visit #8 (1 year) was calculated. This derived change score is summarized by group.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>4,000 IU vitamin D3 daily for one year
vitamin D3: 4,000 IU daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo daily for one year
Placebo daily for one year: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Slope (Trajectory) or the Change in PSA Level Over Time</title>
          <description>Change in PSA (ng/mL) from baseline to 1 year visit, which include the baseline through 1 year follow-up.</description>
          <population>Linear regression was applied to each subject's data with Log(PSA +1) as the outcome. Based on the fitted model, the change in PSA from visit #1 (baseline) to visit #8 (1 year) was calculated. This derived change score is summarized by group.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" lower_limit="-0.20" upper_limit="1.44"/>
                    <measurement group_id="O2" value="0.27" lower_limit="-0.57" upper_limit="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Positive Biopsy Cores (Out of Twelve) Compared to the Corresponding Values Assessed Before Enrollment</title>
        <description>Change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation.</description>
        <time_frame>1 year</time_frame>
        <population>Each subject had 12 cores measured at each of the pre and post prostate biopsies. The variable summarized is the number of positive cores per subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D3</title>
            <description>4,000 IU vitamin D3 daily for one year
vitamin D3: 4,000 IU daily for one year</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo daily for one year
Placebo daily for one year: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Positive Biopsy Cores (Out of Twelve) Compared to the Corresponding Values Assessed Before Enrollment</title>
          <description>Change in the number of positive cores per subject from the pre-study prostate biopsy to the repeat prostate biopsy following study participation.</description>
          <population>Each subject had 12 cores measured at each of the pre and post prostate biopsies. The variable summarized is the number of positive cores per subject.</population>
          <units>cores per subject</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-1.00" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-1.00" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Recruitement Period was OCT 2010 - DEC 2012. Final particpant study visit was OCT 2013. Adverse Event data was collected over a period of 3 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>4,000 IU vitamin D3 daily for one year
vitamin D3: 4,000 IU daily for one year</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Placebo daily for one year
Placebo daily for one year: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sebastiano Gattoni-Celli, M.D.</name_or_title>
      <organization>Ralph H. Johnson VA Medical Center</organization>
      <phone>843-876-5103</phone>
      <email>gatttonis@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

